Retigabine for the adjunctive treatment of partial onset seizures in epilepsy

  • Technology appraisal guidance
  • TA232
  • Published: 

The guidance has been withdrawn because GlaxoSmithKline has discontinued retigabine (Trobalt) due to limited usage.